LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Arcus Biosciences Inc

Geschlossen

BrancheGesundheitswesen

11.99 2.48

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11.59

Max

12.39

Schlüsselkennzahlen

By Trading Economics

Verkäufe

132M

160M

Angestellte

627

EBITDA

126M

4M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+161.28% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

255M

1.2B

Vorheriger Eröffnungskurs

9.51

Vorheriger Schlusskurs

11.99

Nachrichtenstimmung

By Acuity

50%

50%

167 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Neutral Evidence

Arcus Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Sept. 2025, 23:01 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17. Sept. 2025, 22:48 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17. Sept. 2025, 21:59 UTC

Ergebnisse

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17. Sept. 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17. Sept. 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17. Sept. 2025, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17. Sept. 2025, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17. Sept. 2025, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17. Sept. 2025, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17. Sept. 2025, 22:18 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17. Sept. 2025, 21:00 UTC

Ergebnisse

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17. Sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. Sept. 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Sept. 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17. Sept. 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17. Sept. 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17. Sept. 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17. Sept. 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17. Sept. 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Sept. 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17. Sept. 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17. Sept. 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17. Sept. 2025, 17:15 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17. Sept. 2025, 17:06 UTC

Akquisitionen, Fusionen, Übernahmen

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17. Sept. 2025, 16:51 UTC

Ergebnisse

Correct: Exor 1H Net Loss -EUR624M

17. Sept. 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Sept. 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17. Sept. 2025, 16:25 UTC

Ergebnisse

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17. Sept. 2025, 16:23 UTC

Ergebnisse

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Peer-Vergleich

Kursveränderung

Arcus Biosciences Inc Prognose

Kursziel

By TipRanks

161.28% Vorteil

12-Monats-Prognose

Durchschnitt 30.7 USD  161.28%

Hoch 52 USD

Tief 12 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Arcus Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

9

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

8.01 / 8.75Unterstützung & Widerstand

Kurzfristig

Neutral Evidence

Mittelfristig

Neutral Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

167 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat